News

Popular Weight-Loss Medications Show Surprising Skin Benefit, with Important Caveats

Published in JAMA Dermatology, the retrospective cohort analysis spanned 15 French medical centers and included 66 adults diagnosed with HS who also had obesity and most (86 %) were diabetic. These patients were treated with GLP-1 receptor agonists—primarily semaglutide, but also dulaglutide and liraglutide—with a median treatment duration of 18.5 months.

• By Newsdesk
• New Delhi
• Aug 29, 2025

News

A compelling new study reveals that GLP-1 drugs, such as Ozempic and Wegovy, widely known for aiding weight loss and managing type 2 diabetes, may offer unexpected relief for patients suffering from hidradenitis suppurativa (HS)—a painful, chronic skin condition marked by recurrent lumps in areas like the underarms and groin.

The Study at a Glance

Published in JAMA Dermatology, the retrospective cohort analysis spanned 15 French medical centers and included 66 adults diagnosed with HS who also had obesity and most (86 %) were diabetic. These patients were treated with GLP-1 receptor agonists—primarily semaglutide, but also dulaglutide and liraglutide—with a median treatment duration of 18.5 months.

Outcomes were evaluated at approximately six months and again at the final follow-up. By six months:

• 54 % of patients achieved a minimum one-grade improvement on the HS Physician’s Global Assessment (HS-PGA); this rose to 62 % by the end of the study.
• 67 % experienced fewer HS flare-ups by the last consultation.
• 60 % reported reductions in pain levels.
• Improvements were also noted in suppuration and dermatology-related quality of life scores.

Why the Improvement?

Dermatology experts suggest a two-pronged mechanism may be at play:

1. Indirect Benefits: Weight loss resulting from GLP-1 therapy may reduce mechanical friction, moisture, and tissue inflammation in skin folds—areas particularly affected in HS.
2. Direct Anti-inflammatory Effects: Emerging evidence indicates GLP-1 receptor agonists may dampen inflammatory cytokine production and modulate immune responses to promote skin healing.

A Note of Caution

While these outcomes are promising, the research has limitations:

• The retrospective design and varied concurrent HS treatments make it difficult to isolate the effects of GLP-1 therapy.
• The findings largely reflect the experience of obese, diabetic patients, and may not generalize to other HS populations.
• GLP-1 medications are not currently approved for treating HS, and their off-label use must be carefully considered by healthcare providers.

The study authors and dermatologists urge a measured approach and stress the need for randomized controlled trials to confirm efficacy, clarify mechanisms, and identify which patients may benefit most.

GLP-1 medications like semaglutide show potential beyond weight management including possibly easing symptoms of HS. But until more rigorous trials are conducted, they remain an experimental option that should be approached with medical supervision.

This emerging therapeutic possibility may ultimately broaden treatment options for HS, but for now, cautious optimism is the order of the day.